Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02641106 · ClinicalTrials.gov registry record · NA
VDOT for Monitoring Adherence to LTBI Treatment
A NA study, sponsored by University of California, San Diego.
- Completed
- Registry status
- NA
- Development phase
- 129
- Enrollment target
NCT02641106 is a NA study that has completed, run by University of California, San Diego. The registered enrollment target is 129 participants.
The verdict
NCT02641106, a NA study, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- NA
- Development phase
- 129 participants
- Enrollment target
Study Summary
The three-month short-course treatment with isoniazid \[H\] and rifapentine \[P\] (3HP) recently recommended by the Centers for Disease Control and Prevention could dramatically increase the number of persons starting and completing treatment for latent tuberculosis infection (LTBI), but TB providers nationwide are hamstrung by the requirement that 3HP only be administered by directly observed therapy (DOT) in which patients are watched taking each medication dose in-person. We developed a novel mHealth application that allows patients to make and send videos of each medication dose ingested that are watched by healthcare providers via a HIPAA-compliant website to remotely monitor LTBI treatment adherence (Video DOT \[VDOT\]). This study will determine whether monitoring patients with VDOT achieves higher treatment completion rates and greater patient acceptability at lower cost than clinic-based in-person DOT.
Interventions
- OTHER Video Directly Observed Therapy
- OTHER In-Person DOT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2016-03-08 |
| Est. Completion | 2020-06-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02641106
The ClinicalTrials.gov registry entry for NCT02641106 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 129 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Video Directly Observed Therapy is the first listed.
NCT02641106 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02641106 about?
NCT02641106 is a clinical study titled "VDOT for Monitoring Adherence to LTBI Treatment". The three-month short-course treatment with isoniazid \[H\] and rifapentine \[P\] (3HP) recently recommended by the Centers for Disease Control and Prevention could dramatically increase the number of persons starting and completing treatment for latent tuberculosis infection (LTBI), but TB provider...
What is the current status of trial NCT02641106?
This trial is currently completed. It is a NA study. The enrollment target is 129 participants. The study started on 2016-03-08. Estimated completion is 2020-06-30.
What interventions are being tested in trial NCT02641106?
The interventions under investigation include: Video Directly Observed Therapy (OTHER), In-Person DOT (OTHER).
Who is sponsoring clinical trial NCT02641106?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.